KIAA1614 is a gene located on chromosome 1 with predicted roles in cell polarity and cellular localization based on GO annotations. However, its primary biological function remains incompletely characterized. The gene has emerged as a potential therapeutic target through integrative multi-omics analysis of sporadic Creutzfeldt-Jakob disease (sCJD), identified among five high-evidence targets for this fatal neurodegenerative condition 1. KIAA1614 shows dysregulation across multiple disease contexts: it is hypermethylated in ectopic pregnancy chorionic tissue and may contribute to abnormal embryonic development 2, and is transcriptionally upregulated in type 1 diabetes mellitus complications including neuropathy, ketoacidosis, and polycystic ovary syndrome 3. Additionally, genetic variants near KIAA1614 demonstrate suggestive associations with progression from inflammatory to complicated Crohn's disease 4, and the gene shows methylation alterations following metformin administration in healthy individuals, implicating involvement in energy homeostasis and inflammatory pathways 5. KIAA1614 is also significantly hypermethylated in ulcerative colitis, with promoter hypermethylation correlating with transcriptional silencing 6. Furthermore, genetic variants at this locus associate with circulating cellular adhesion protein levels in cardiovascular disease contexts 7. These findings collectively suggest KIAA1614 involvement in cell adhesion, cellular polarity, and inflammatory/metabolic homeostasis, though mechanistic details require further investigation.